8-K current report · filed Oct 29, 2026

PTC THERAPEUTICS, INC. (PTCT) 8-K Current Report: October 29, 2026

Item EX-99.1Item EX-99.2Item 2.02Item 7.01PTCT overview

Short answer

PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q3 2026 financial results announced for quarter ended September 30, 2026.

PTC THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1
  • Investor focus: quarterly revenue, cash position, operating expenses and pipeline updates in the accompanying release

Item 7.01 · Regulation FD Disclosure

  • Conference call scheduled for October 29, 2026 at 4:30 p.m. Eastern
  • Management to review quarter ended September 30, 2026 financial results
  • Updated corporate presentation signals additional corporate and pipeline updates for investors
  • Presentation available through the company’s Investors Events and Presentations page

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $357.6M, up from $201.7M, led by Sephience product revenue of $181.9M
  • Full-year 2026 revenue guidance raised to $1.29B-$1.32B, product revenue to $960M-$990M
  • Sephience exceeded 2,000 active patients globally, with Q3 US revenue $145M and ex-US revenue $37M
  • ST-920 acquired for $111M upfront, plus up to $100M in regulatory milestones, creating 2027 launch potential
  • Net loss $51.7M, including $111M acquired in-process R&D, while cash and securities reached $2.13B

Item EX-99.2 · Exhibit EX-99.2

  • 2026 product revenue guidance: $1.29-$1.32B, representing 64%-69% YoY growth
  • Total revenue guidance: $960-$990M, with non-GAAP OpEx of $680-$720M
  • Sephience generated $458M global revenue YTD through September 30, supporting launch-driven growth
  • Cash balance $2.1B, with management targeting 2026 cash-flow breakeven
  • ST-920 BLA submission for accelerated approval expected in Q4 2026, creating a near-term regulatory catalyst

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PTC THERAPEUTICS, INC. 8-K filings

Get the next PTCT 8-K as it lands

Follow PTCT for push alerts, or ask the research agent what this filing means.